Cefetecol
Cefetecol (GR69153) is a semisynthetic β-lactam antibacterial agent and α-glucosidase inhibitor (yeast IC50 = 2.1 μM; Ki = 5.78 μM) that crosses the blood-brain barrier. Cefetecol reduces blood glucose levels in Streptozotocin-induced diabetic mice. Cefetecol decreases the mRNA expression of GSK-3, PPAR-γ, and UCP-3. Cefetecol induces bacterial cell filamentation and exhibits bactericidal activity against Gram-positive and Gram-negative bacteria. Cefetecol is used in the study of diabetes and bacterial infections.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 117211-03-7
- 分子式: C20H17N5O9S2
- 分子量:535.51
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体内実験
Cefetecol (0.10-0.95 mg/mouse; subcutaneous injection; single or three doses; 7-10 days) is effective against experimental intraperitoneal infection in mice, with ED50 values of 0.10 to 0.95 mg/mouse for single dosing and 0.02 to 0.31 mg/mouse for three doses[3].
Cefetecol (subcutaneous injection; twice) effectively inhibits the formation of experimental subcutaneous abscesses caused by S. aureus in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6NKist (female, streptozotocin-induced diabetic model)[1]
-
Dosage:30 mg/kg/day
-
Administration:i.p.; daily; 14 days
-
Result:Decreased blood glucose levels by as much as 30% (195.3 mg/dl) compared to control animals.
Slightly decreased mRNA expression levels of GSK-3, PPAR-γ and UCP-3 compared to the internal control GAPDH.
Did not significantly change the expression levels of aldose reductase and PTP-1B.
-
Animal Model:ddY (male, 22~25 g, 7 mice/group)[3]
-
Dosage:0.10-0.95 mg/mouse (single); 0.02-0.31 mg/mouse (three doses)
-
Administration:s.c.; once (1 hour after challenge) or three times (1-hour intervals starting 1 hour after challenge); 7~10 days
-
Result:Produced ED50 values of 0.17, 0.21, 0.10, 0.12, 0.36, 0.12, 0.28, 0.10, 0.22, 0.35, and 0.95 mg/mouse against S. pyogenes J-12, S. pyogenes J-13, S. pneumoniae TO-1, E. coli 11, E. coli 49, E. coli 54, K. pneumoniae 3K25, K. pneumoniae 15C, P. mirabilis 9', P. mirabilis 1287, and P. mirabilis JU-453, respectively, with single administration.
Produced ED50 values of 0.02, 0.07, 0.13, 0.18, 0.20, and 0.31 mg/mouse against S. pneumoniae TO-1, E. coli 11, E. coli 49, K. pneumoniae 3K25, P. mirabilis 9', and P. mirabilis JU-453, respectively, with three doses.
Exhibited good efficacy against P. mirabilis JU-453 (MIC of 200 μg/mL).
化学情報
-
CAS 番号 117211-03-7
-
分子量 535.51
-
分子式 C20H17N5O9S2
-
SMILES
O=C1N2[C@@](SCC=C2C(O)=O)([H])[C@@H]1NC(/C(C3=CSC(N)=N3)=N\O[C@@H](C4=CC(O)=C(C=C4)O)C(O)=O)=O
-
別名
GR69153
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Lee DS, et al. Ceftezole, a cephem antibiotic, is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity. International journal of molecular medicine. 2007 Sep;20(3):379-83. [Content Brief]
[2]. Harada Y, et al. Ceftezole, a new cephalosporin C derivative II. Distribution and excretion in parenteral administration. J Antibiot (Tokyo). 1976 Oct;29(10):1071-82. [Content Brief]
[3]. Noto T, et al. Ceftezole, a new cephalosporin C derivative I. In vitro and in vivo antimicrobial activity. The Journal of antibiotics. 1976 Oct;29(10):1058-70. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Cefetecol 関連分類
HY-159796A 関連分類
Powered by Bioz